

US dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited.

Income statement

	2022 £m	2022 \$m	Q4 2022 £m	Q4 2022 \$m
TURNOVER	29,324	36,344	7,376	8,751
Cost of sales	(9,554)	(11,841)	(2,238)	(2,655)
Gross profit	19,770	24,503	5,138	6,096
Selling, general and administration	(8,372)	(10,376)	(2,438)	(2,892)
Research and development	(5,488)	(6,802)	(1,797)	(2,132)
Royalty income	758	939	206	244
Other Operating income	(235)	(291)	759	900
OPERATING PROFIT	6,433	7,973	1,868	2,216
Finance income	76	94	26	31
Finance expense	(879)	(1,090)	(270)	(320)
Share of after tax losses of JV and associates	(2)	(2)	2	2
PROFIT BEFORE TAXATION	5,628	6,975	1,626	1,929
Taxation	(707)	(876)	(1)	(1)
PROFIT AFTER TAXATION FROM CONTINUING OPERATIONS	4,921	6,099	1,625	1,928
Profit after taxation from discontinued operations and other gains/(losses) from the demerger	3,049	3,779	(5)	(6)
Re-measurement of discontinued operations distributed to shareholders on demerger	7,651	9,483	-	-
PROFIT AFTER TAXATION FROM DISCONTINUED OPERATIONS	10,700	13,262	(5)	(6)
PROFIT AFTER TAX FOR THE PERIOD	15,621	19,361	1,620	1,922
Profit attributable to non-controlling interests from continuing operations	460	570	125	148
Profit attributable to shareholders from continuing operations	4,461	5,529	1,500	1,780
Profit attributable to non-controlling interests from discontinued operations	205	254	-	-
Profit attributable to shareholders from discontinued operations	10,495	13,008	(5)	(6)
	<u>15,621</u>	<u>19,361</u>	<u>1,620</u>	<u>1,922</u>
Profit attributable to non-controlling interests	665	824	125	148
Profit attributable to shareholders	14,956	18,537	1,495	1,774
	<u>15,621</u>	<u>19,361</u>	<u>1,620</u>	<u>1,922</u>
EARNINGS PER SHARE FROM CONTINUING OPERATIONS	110.8p	137.3c	37.2p	44.1c
EARNINGS PER SHARE FROM DISCONTINUED OPERATIONS	260.6p	323.0c	(0.1)p	(0.1)c
TOTAL EARNINGS PER SHARE	<u>371.4p</u>	<u>460.3c</u>	<u>37.1p</u>	<u>44.0c</u>
Diluted earnings per share from continuing operations	109.2p	135.3c	36.6p	43.5c
Diluted earnings per share from discontinued operations	257.0p	318.6c	(0.1)p	(0.1)c
Total diluted earnings per share	<u>366.2p</u>	<u>453.9c</u>	<u>36.5p</u>	<u>43.4c</u>

In the income statement above US dollar results for the three months period and for the year ended 31 December 2022 are calculated using average rates for those periods.

In the detailed sales tables below US dollar results for the year ended December 2022 are calculated using average rates for the year. US dollar results for the three months ended 31 December 2022 are calculated as the difference between the year-end results translated into US dollars and US dollar results previously published for the nine months ended 30 September 2022.

Specialty Medicines turnover – year ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	5,749	3,756	1,310	683	7,126	4,655	1,624	847
<i>Dolutegravir products</i>	5,191	3,311	1,239	641	6,433	4,104	1,535	794
<i>Tivicay</i>	1,381	823	273	285	1,711	1,020	339	352
<i>Triumeq</i>	1,799	1,217	361	221	2,230	1,509	447	274
<i>Juluca</i>	636	494	127	15	788	612	157	19
<i>Dovato</i>	1,375	777	478	120	1,704	963	592	149
<i>Rukobia</i>	82	79	3	-	102	98	4	-
<i>Cabenuva</i>	340	294	40	6	422	364	50	8
<i>Apretude</i>	41	41	-	-	51	51	-	-
Other	95	31	28	36	118	38	35	45
Oncology	602	313	253	36	746	388	313	45
<i>Zejula</i>	463	235	194	34	574	291	240	43
<i>Blenrep</i>	118	66	52	-	146	82	64	-
<i>Jemperli</i>	21	13	8	-	26	16	10	-
Other	-	(1)	(1)	2	-	(1)	(1)	2
Immuno-inflammation, respiratory and other	2,609	1,830	366	413	3,233	2,268	454	511
<i>Benlysta</i>	1,146	949	83	114	1,420	1,177	103	140
<i>Nucala</i>	1,423	881	300	242	1,764	1,092	372	300
Other	40	-	(17)	57	50	-	(21)	71
Specialty Medicines excluding pandemic	8,960	5,899	1,929	1,132	11,105	7,311	2,391	1,403
Pandemic	2,309	828	456	1,025	2,862	1,026	566	1,270
<i>Xevudy</i>	2,309	828	456	1,025	2,862	1,026	566	1,270
Specialty Medicines	11,269	6,727	2,385	2,157	13,967	8,337	2,957	2,673

Specialty Medicines turnover – three months ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	1,678	1,163	344	171	2,016	1,400	411	205
<i>Dolutegravir products</i>	1,482	998	320	164	1,777	1,200	381	196
<i>Tivicay</i>	373	235	69	69	445	282	83	81
<i>Triumeq</i>	479	340	83	56	573	407	98	67
<i>Juluca</i>	192	155	32	5	231	186	38	7
<i>Dovato</i>	438	268	136	34	528	325	162	41
<i>Rukobia</i>	26	25	1	-	32	30	2	-
<i>Cabenuva</i>	129	112	15	2	157	136	18	3
<i>Apretude</i>	21	21	-	-	26	26	-	-
Other	20	7	8	5	24	8	10	6
Oncology	157	78	67	12	187	93	80	14
<i>Zejula</i>	125	63	52	10	150	75	62	13
<i>Blenrep</i>	27	11	16	-	32	13	19	-
<i>Jemperli</i>	5	5	-	-	6	6	-	-
Other	0	(1)	(1)	2	-	(1)	(1)	2
Immuno-inflammation, respiratory and other	721	512	94	115	863	613	113	137
<i>Benlysta</i>	326	271	23	32	390	324	28	37
<i>Nucala</i>	395	242	85	68	474	290	102	82
Other	-	(1)	(14)	15	0	(1)	(17)	18
Specialty Medicines excluding pandemic	2,556	1,753	505	298	3,066	2,107	603	356
Pandemic	125	10	19	96	120	(1)	17	104
<i>Xevudy</i>	125	10	19	96	120	(1)	17	104
Specialty Medicines	2,681	1,763	524	394	3,186	2,106	621	459

Vaccines turnover – year ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Meningitis	1,116	573	362	181	1,383	711	448	224
<i>Bexsero</i>	753	333	337	83	933	413	417	103
<i>Menveo</i>	345	240	20	85	428	298	25	105
<i>Other</i>	18	-	5	13	22	-	6	16
Influenza	714	549	57	108	885	680	71	134
<i>Fluarix, FluLaval</i>	714	549	57	108	885	680	71	134
Shingles	2,958	1,964	688	306	3,666	2,434	853	379
<i>Shingrix</i>	2,958	1,964	688	306	3,666	2,434	853	379
Established Vaccines	3,085	1,157	720	1,208	3,824	1,434	892	1,498
<i>Infanrix, Pediarix</i>	594	327	131	136	736	405	162	169
<i>Boostrix</i>	594	360	138	96	736	446	171	119
Hepatitis	571	343	142	86	708	425	176	107
<i>Rotarix</i>	527	95	122	310	653	118	151	384
<i>Synflorix</i>	305	-	34	271	378	-	42	336
<i>Priorix, Priorix Tetra, Varilrix</i>	188	10	97	81	233	12	121	100
<i>Cervarix</i>	117	-	22	95	145	-	27	118
<i>Other</i>	189	22	34	133	234	27	42	165
Vaccines excluding pandemic	7,873	4,243	1,827	1,803	9,758	5,259	2,264	2,235
Pandemic vaccines	64	-	57	7	79	-	70	9
Pandemic adjuvant	64	-	57	7	79	-	70	9
Vaccines	7,937	4,243	1,884	1,810	9,837	5,259	2,334	2,244

Vaccines turnover – three months ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Meningitis	228	73	101	54	268	83	120	65
<i>Bexsero</i>	150	36	92	22	176	40	109	27
<i>Menveo</i>	77	37	8	32	91	43	10	38
<i>Other</i>	1	-	1	-	1	-	1	-
Influenza	276	217	29	30	335	263	36	36
<i>Fluarix, FluLaval</i>	276	217	29	30	335	263	36	36
Shingles	769	480	204	85	918	571	245	102
<i>Shingrix</i>	769	480	204	85	918	571	245	102
Established Vaccines	743	218	188	337	884	255	224	405
<i>Infanrix, Pediarix</i>	111	48	30	33	130	55	35	40
<i>Boostrix</i>	131	73	31	27	155	86	37	32
Hepatitis	126	64	36	26	149	74	43	32
<i>Rotarix</i>	147	21	32	94	176	25	38	113
<i>Synflorix</i>	68	-	10	58	80	-	12	68
<i>Priorix, Priorix Tetra, Varilrix</i>	50	9	24	17	60	11	29	20
<i>Cervarix</i>	26	-	7	19	31	-	8	23
<i>Other</i>	84	3	18	63	102	3	22	77
Vaccines excluding pandemic	2,016	988	522	506	2,405	1,172	625	608
Pandemic vaccines	58	-	57	1	71	-	70	1
Pandemic adjuvant	58	-	57	1	71	-	70	1
Vaccines	2,074	988	579	507	2,476	1,172	695	609

General Medicines turnover – year ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	6,548	3,209	1,384	1,955	8,115	3,977	1,716	2,422
<i>Arnuity Ellipta</i>	56	48	-	8	69	59	-	10
<i>Anoro Ellipta</i>	483	233	165	85	599	289	205	105
<i>Avamys/Veramyst</i>	321	-	65	256	398	-	81	317
<i>Flixotide/Flovent</i>	545	353	74	118	676	438	92	146
<i>Incruse Ellipta</i>	196	104	64	28	243	129	79	35
<i>Relvar/Breo Ellipta</i>	1,145	498	347	300	1,419	617	430	372
<i>Seretide/Advair</i>	1,159	308	287	564	1,437	382	356	699
<i>Trelegy Ellipta</i>	1,729	1,253	236	240	2,142	1,553	292	297
<i>Ventolin</i>	771	411	116	244	955	509	144	302
Other Respiratory	143	1	30	112	177	1	37	139
Other General Medicines	3,570	363	695	2,512	4,424	450	862	3,112
Dermatology	376	(1)	107	270	466	(1)	133	334
Augmentin	576	-	151	425	714	-	187	527
Avodart	330	-	107	223	409	-	133	276
Lamictal	511	265	109	137	633	328	135	170
Other	1,777	99	221	1,457	2,202	123	274	1,805
General Medicines	10,118	3,572	2,079	4,467	12,539	4,427	2,578	5,534

General Medicines turnover – three months ended 31 December 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	1,682	778	374	530	2,007	925	448	634
<i>Arnuity Ellipta</i>	11	9	-	2	13	11	-	2
<i>Anoro Ellipta</i>	138	68	47	23	166	82	57	27
<i>Avamys/Veramyst</i>	82	-	14	68	98	-	17	81
<i>Flixotide/Flovent</i>	134	75	22	37	160	89	27	44
<i>Incruse Ellipta</i>	39	16	16	7	46	18	19	9
<i>Relvar/Breo Ellipta</i>	249	72	94	83	294	82	112	100
<i>Seretide/Advair</i>	330	105	75	150	396	127	90	179
<i>Trelegy Ellipta</i>	457	321	65	71	545	383	77	85
<i>Ventolin</i>	206	111	33	62	246	132	40	74
Other Respiratory	36	1	8	27	43	1	9	33
Other General Medicines	939	95	178	666	1,121	114	213	794
Dermatology	99	(1)	28	72	118	(1)	34	85
Augmentin	167	-	44	123	201	-	53	148
Avodart	82	-	26	56	97	-	31	66
Lamictal	132	71	29	32	157	85	35	37
Other	459	25	51	383	548	30	60	458
General Medicines	2,621	873	552	1,196	3,128	1,039	661	1,428

Commercial operations turnover

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Year ended 31 December 2022	29,324	14,542	6,348	8,434	36,344	18,023	7,868	10,453
Three months ended 31 December 2022	7,376	3,624	1,655	2,097	8,793	4,318	1,977	2,498

Balance sheet

	31-Dec-22 £m	31-Dec-22 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,933	10,754
Right of use assets	687	828
Goodwill	7,046	8,483
Other intangible assets	14,318	17,237
Investments in associates and joint ventures	74	89
Other investments	1,467	1,766
Deferred tax asset	5,658	6,812
Other non-current assets	1,194	1,437
Total non-current assets	39,377	47,406
Current assets		
Inventories	5,146	6,195
Current tax recoverable	405	488
Trade and other receivables	7,053	8,491
Derivative financial instruments	190	229
Current equity investments	4,087	4,920
Liquid investments	67	81
Cash & cash equivalents	3,723	4,482
Assets held for sale/distribution	98	118
Total current assets	20,769	25,004
TOTAL ASSETS	60,146	72,410
LIABILITIES		
Current liabilities		
Short-term borrowings	(3,952)	(4,758)
Contingent consideration liabilities	(1,289)	(1,552)
Trade and other payables	(16,263)	(19,579)
Derivative financial instruments	(183)	(220)
Current tax payable	(471)	(567)
Short term provisions	(652)	(785)
Total current liabilities	(22,810)	(27,461)
Non-current liabilities		
Long-term borrowings	(17,035)	(20,509)
Corporation tax payable	(127)	(153)
Deferred tax liabilities	(289)	(348)
Pension and other post-employment benefits	(2,579)	(3,105)
Other provisions	(532)	(640)
Contingent consideration liabilities	(5,779)	(6,957)
Other non-current liabilities	(899)	(1,082)
Total non-current liabilities	(27,240)	(32,794)
TOTAL LIABILITIES	(50,050)	(60,255)
NET ASSETS	10,096	12,155
EQUITY		
Share Capital	1,347	1,622
Share premium account	3,440	4,141
Retained earnings	4,363	5,253
Other reserves	1,448	1,743
Shareholders' equity	10,598	12,759
Non-controlling Interests	(502)	(604)
TOTAL EQUITY	10,096	12,155

US dollar amounts shown in the balance sheet above are calculated using closing rate at 31 December 2022.